文献速递肾小球疾病慢性肾脏病

系统性红斑狼疮低级别蛋白尿患者肾脏受累的短期与长期进展

Short- and Long-Term Progression of Kidney Involvement in Systemic Lupus Erythematosus Patients with Low-Grade Proteinuria.
PubMed 文献 · Clin J Am Soc Nephrol · 2022-07-26

研究基于爱因斯坦风湿病登记数据库,纳入151例尿蛋白肌酐比≥0.2且<0.5 g/g的系统性红斑狼疮患者,随访发现76例(50%)进展至≥0.5 g/g,中位进展时间1.2年;前2年20例活检中16例示活动性狼疮肾炎;低补体、短病程等与进展相关。

要点

  • 低级别蛋白尿(尿蛋白肌酐比≥0.2且<0.5 g/g)患者中50%进展至≥0.5 g/g,中位时间1.2年。
  • 前2年20例活检中16例示活动性、可治疗的狼疮肾炎。
  • 低补体、短病程、高血压、糖尿病、年轻、血尿与进展相关。

核心结论

  • 在研究的纵向队列中,超过一半的低级别蛋白尿系统性红斑狼疮患者在短时间内进展至尿蛋白肌酐比≥0.5 g/g。

研究设计与样本

  • 从爱因斯坦风湿病登记数据库识别无已知狼疮肾炎、新发尿蛋白肌酐比≥0.2且<0.5 g/g的系统性红斑狼疮患者,共纳入151例;随访期间随机尿蛋白肌酐比≥0.5 g/g定义为进展者,2年内进展定义为快速进展者。

主要发现

  • 151例中76例(50%)进展至尿蛋白肌酐比≥0.5 g/g,其中44例接受了临床指征活检。
  • 从尿蛋白肌酐比≥0.2且<0.5 g/g至进展的中位(四分位距)时间为1.2(0.3-3.0)年。
  • 前2年进行的20例活检中,16例标本显示活动性、可治疗的狼疮肾炎。
  • 低补体和低级别蛋白尿起病时较短的SLE病程与进展至显性蛋白尿相关。
  • 其他相关因素包括高血压、糖尿病、较年轻年龄和血尿。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Lupus nephritis remains a common cause of morbidity and mortality in systemic lupus erythematosus (SLE). Current guidelines recommend performing a kidney biopsy at a urine protein-creatinine ratio of ≥0.5 g/g. However, cross-sectional studies reported a high prevalence of active histologic lupus nephritis lesions, and even chronic irreversible scarring, in patients with low-grade proteinuria. This study was initiated to assess disease progression in patients with SLE and low-grade proteinuria to identify risk factors for progression to overt proteinuria suggestive of clinical lupus nephritis. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Patients with SLE who had an incident urinary protein-creatinine ratio of ≥0.2 and <0.5 g/g without known lupus nephritis were identified from the Einstein Rheumatic Disease Registry. Patients who developed a random urinary protein-creatinine ratio of ≥0.5 g/g with or without biopsy during the follow-up period were defined as "progressors." Patients who progressed to a urinary protein-creatinine ratio of ≥0.5 g/g within 2 years of developing a urinary protein-creatinine ratio of ≥0.2 and <0.5 g/g were defined as "fast progressors," a subgroup expected to benefit most from early biopsies and therapeutic interventions. RESULTS: Among 151 eligible patients with SLE and low-grade proteinuria at study entry, 76 (50%) progressed to a urinary protein-creatinine ratio of ≥0.5 g/g, of which 44 underwent a clinically indicated biopsy. The median (interquartile range) time from a urinary protein-creatinine ratio of ≥0.2 and <0.5 g/g to progression was 1.2 (0.3-3.0) years. Of the 20 biopsies performed in the first 2 years, 16 specimens showed active, treatable lupus nephritis. Low complement and shorter SLE duration at low-grade proteinuria onset were associated with progression to overt proteinuria across different analyses. Other associated factors included hypertension, diabetes mellitus, younger age, and the presence of hematuria. CONCLUSIONS: In this longitudinal cohort of patients with SLE and low-grade proteinuria at study entry, over half progressed to a urinary protein-creatinine ratio of ≥0.5 g/g in a short time period.

来源:Clin J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Wang S, Spielman A, Ginsberg M, et al. Short- and Long-Term Progression of Kidney Involvement in Systemic Lupus Erythematosus Patients with Low-Grade Proteinuria. Clin J Am Soc Nephrol. 2022. PMID: 35882508. doi:10.2215/CJN.01280122

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。